BiotechTube

AMG334 + Oral Prophylactic

ApprovedCompleted
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Episodic Migraine

Conditions

Episodic Migraine

Trial Timeline

May 15, 2019 → Sep 30, 2022

NCT ID
NCT03927144

About AMG334 + Oral Prophylactic

AMG334 + Oral Prophylactic is a approved stage product being developed by Novartis for Episodic Migraine. The current trial status is completed. This product is registered under clinical trial identifier NCT03927144. Target conditions include Episodic Migraine.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT03927144ApprovedCompleted

Competing Products

19 competing products in Episodic Migraine

See all competitors
ProductCompanyStageHype Score
GalcanezumabEli LillyPhase 3
77
Galcanezumab + PlaceboEli LillyPhase 3
77
Galcanezumab + PlaceboEli LillyPhase 3
77
Galcanezumab + PlaceboEli LillyPhase 3
77
BOTOX + PlaceboAbbViePhase 3
77
Atogepant 60 mgAbbViePhase 3
77
Atogepant + UbrogepantAbbVieApproved
85
Atogepant + Placebo-Matching AtogepantAbbViePhase 3
77
SOM230 + PlaceboNovartisPhase 2
52
AMG334 (70 mg) Pre-Filled Syringe (PFS) + Placebo Pre-Filled Syringe (PFS)NovartisPhase 3
77
ErenumabNovartisPhase 3
77
Placebo + AMG 301AmgenPhase 2
51
Placebo + MS Contin (morphine sulfate, controlled release) + EMBEDA (morphine sulfate / naltrexone hydrochloride)PfizerPhase 1
32
Eptinezumab + PlaceboLundbeckPhase 3
74
Eptinezumab + PlaceboLundbeckPhase 3
74
Botulinum toxin type A + Botulinum toxin type A + Botulinum toxin type A + Botulinum toxin type AIpsenPhase 3
74
IPN10200 + IPN10200 dose A + IPN10200 dose BIpsenPhase 2
49
DFN-11Dr. Reddy's LaboratoriesPhase 3
74
MethylprednisoloneBrain BiotechApproved
77

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85